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的最优化条件为：SPC/MMC 投料比 3:1，药物浓度 0.8 mg/ml，反应温度为 40℃。
产品呈深紫色，粘稠粉末状，复合率达到 95.2%。 
(2) PLA 空白纳米粒子的制备及性质研究：采用透析法制备 PLA 空白纳米
粒子，对纳米粒子的形貌、粒径分布、分散度及理化性质进行表征。考察不同
PLA 溶液浓度对粒子粒径的影响。结果表明：制备的 PLA 空白纳米粒子具有
良好的微观结构，纳米粒子的表面圆滑，分散性好；通过控制 PLA 溶液浓度大
小，可以将粒子粒径控制分布在 200~600 nm 之间，在固定其它条件的情况下，
PLA 溶液的浓度越大，制备的粒子的粒径越大。 



















100~300 nm；在固定其它条件的情况下，增大 PLA 或复合物的浓度，制备的粒
子的粒径都会增大，载药量也会相应增大，但包封率减小；不同条件下制备的
载药量和包封率不尽相同，但纳米粒子的载药量保持在 5~20%之间，包封率在






















Cancer is a great threat to the health of human beings. Although the traditional 
intravenous chemotherapy has a certain effect, it’s often difficult for patients to endure 
because of severe side effects all over the body. In recent years, great success has been 
made for chemotherapy using controlled or sustained release drug delivery system. 
Dialysis method is an acceptable simple and effective preparation method for drug 
loaded polymer nanoparticles, which is expected to be applied in industrial 
production. 
Mitomycin C (MMC) is a broad-spectrum antitumor antibiotic drug. To reduce 
the amount of administration and side effects, MMC-phospholipid complex was first 
prepared. Then, PLA nano-particles containing MMC-phospholipid complex were 
prepared by dialysis method. Furtherly the performance and physical and chemical 
properties of MMC-phospholipid complex and drug loaded PLA nanoparticles were 
studied. The contents are summarized as follows: 
(1) Preparation, optimization and properties of MMC-phospholipid complex: 
Preparation of MMC-phospholipid complex. On the basis of examining the impact of 
different single-factors on the experiment result, orthogonal optimization of 
preparation process was carried out and the complex’s physical and chemical 
properties were characterized. The results showed that MMC-phospholipid complex 
was formed by some weak chemical bonds between MMC and soya lecithin 
molecules, rather than a simple physical mixing and the formation of complex greatly 
increased the liposolubility of MMC. The optimum conditions to prepare drug loaded 
PLA nanoparticles are as follows: SPC/MMC feed ratio is 3:1, drug concentration is 
0.8 mg/ml, and the reaction temperature is 40℃. There were batches of purple, sticky 

















(2) Prepration and properties of blank PLA nanoparticles: PLA blank 
nanoparticles were prepared by dialysis method. The morphology, size distribution, 
dispersion and physical and chemical properties were characterized. The results 
showed that blank PLA nanoparticles were prepared with good micro-structure and 
smooth surface. By controlling the concentration of PLA solution, size of PLA 
nanoparticles could be controlled between 200 and 600 nm. With other conditions 
fixed, the size of nanoparticles would get larger with increasing the concentration of 
PLA. 
(3) Prepration and properties of drug-loaded PLA nanoparticles: 
Drug-loaded PLA nanoparticles were prepared by dialysis method. The morphology, 
size distribution, dispersion and physical and chemical properties were characterized. 
The influence of different concentrations of PLA or drug concentration on the particle 
size, encapsulation efficiency and drug loading content were studied. The effect of 
drug-loaded PLA nanoparticles on tumor cell-killing was studied by MTT test. The 
results showed that: Drug-loaded PLA nanoparticles were preparated with good 
micro-structure, and the size increased 100~300 nm compared to drug free PLA 
nanoparticles; When fixed other conditions, enhancing concentration of PLA or 
complex will lead to the following consequences: the size of nanoparticles and drug 
loading content increased accordingly, but the encapsulation efficiency decreased. 
They varied with different conditions, but the drug loading content remained between 
5% ~ 20%, and the encapsulation efficiency remained between 15% ~ 40%. During 
the drug release process, there was a short initial burst phenomenon, but then became 
stable, with a significant sustained release effect. MTT results showed that 
drug-loaded PLA nanoparticles maintained a raw material of lethal drugs on tumor 
cells. It means that the process of preparation had not destroyed durg’s efficacy. 
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1.1.2  微粒载体的分类 




















图 1.1 聚合物药物载体形式：微球 (a, b), 微胶囊 (c, d), 水凝胶 (e), 胶束 (f) 
Fig. 1.1 Various type of drug-loaded polymeric carrier including nanoparticles (a, 




表 1.1 不同粒径的药物载体体内靶向的部位[3] 






0.1 ~0.2 μm 被网状内皮系统吸收，最后富集于肝、脾中 
1 μm 白细胞吞噬 
2 ~12 μm 毛细血管摄取，不仅可到达肺，也可进入肝、脾 
7 ~12 μm 在肺中富集 
>12 μm 阻滞在毛细血管末端 

























































































































分酸法明胶(A 型)和碱法明胶(B 型)。A 型明胶的等电点为 7~9，B 型明胶稳定而
不易长菌，等电点为 4.7~5。两者的成囊性或成球性无明显差别，可生物降解，
几乎无抗原性，通常可根据药物对酸碱性的要求选用 A 型或 B 型。明胶为淡黄
色至黄色、半透明、微带光泽的颗粒或薄片；无臭，潮湿后易为细菌分解；在水
中久浸即吸水膨胀，并软化形成凝胶，重量可增加 5~10 倍；在热水、醋酸或甘
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